威尼斯赌场澳门

Medicine

Tiandong Pharmaceutical, a subsidiary of Haike Group, devotes itself to improve the living and prolong the lifetime of the people of China and even the whole world through research and development of practical and effective medical solutions. Tiandong Pharmaceutical focuses on the research and development of drugs targeting the blood system and has established a stable cooperative relationship with National Glycoengineering Research Center (NGRC) with respect to the combination of industries, colleges, institutes and users. The company has set up R&D platforms such as postdoctoral research station, Shandong Biochemical Drugs Engineering Laboratory and provincial enterprise technology center, and has successfully undertaken national scientific research projects, including major new drug development, Science and Technology Support Plan, Torch Plan and key new products. Now, it is the owner of more than 20 patent protection items. Tiandong Pharmaceutical participated in formulating the quality standards of five types of domestic low molecular weight heparin, and made an important contribution to the industrialization and quality improvement of low molecular weight heparin in China.

Products

Name of Product
Properties
Description
Enoxaparin sodium injection
A colorless to pale yellow clear liquid; a ratio of molecular weight less than 2000 is 12.0% to 20.0%;
The ratio of the molecular weight between 2000-8000 is 68.0%-82.0%;
A ratio of molecular weight greater than 8000 ≤ 18.0%;
Free sulfate ≤ 0.12%;
Sterile;
Do not detect visible foreign objects;
Bacterial endotoxin <0.010EU/anti-Xa factor potency unit;
The anti-Xa factor titer should be 90%-110% of the labeled amount;
Anti-IIa factor titer 2000IU/ml ≤ anti-IIa factor titer ≤3500IU/ml, etc., in line with US Pharmacopoeia and Chinese registration standards
4000AxaIU injection: prevention of venous thromboembolic disease (prevention of venous thrombosis), especially thrombosis associated with orthopedic or general surgery. 6000AxaIU injection: treatment of established deep vein thrombosis, with or without pulmonary embolism, clinical symptoms are not serious, excluding pulmonary embolism requiring surgery or thrombolytic therapy. Treatment of unstable angina and non-Q-wave myocardial infarction, combined with aspirin. Used in hemodialysis extracorporeal circulation to prevent thrombosis. Treatment of acute ST-segment elevation myocardial infarction in combination with thrombolytic therapy or concurrent with percutaneous coronary intervention (PCI).
Natto heparin calcium
White or off-white powder;
Weight average molecular weight 3600-5000;
N-NO group ≤ 0.25ppm;
Anti-Xa factor activity 95-130 IU / mg;
Anti-Xa factor activity and anti-IIa factor activity ratio 2.5-4.0, etc., in line with European Pharmacopoeia standards.
A raw material for nadroparin calcium injection.
Nadroparin calcium injection is used in surgical procedures for the prevention of venous thromboembolic disease in a moderate or high risk of venous thrombosis. Treatment of established deep vein thrombosis. Combined with aspirin for the treatment of unstable angina and non-Q-wave myocardial infarction in the acute phase. Prevention of blood clot formation during cardiopulmonary bypass in hemodialysis.
Dalteparin sodium
White or off-white powder;
The weight average molecular weight is about 5600-6400;
Anti-Xa factor activity 110-210 IU/mg;
Anti-IIa factor activity 35-100IU/mg;
Anti-Xa factor activity and anti-IIa factor activity ratio of 1.9-3.2, etc., in line with US Pharmacopoeia and European Pharmacopoeia standards.
A raw material for use in dalteparin sodium injection.
Daheparin sodium injection is used to prevent thromboembolic diseases during surgery; prevention of deep vein thrombosis and pulmonary embolism; treatment of established venous thrombosis; prevention of thrombosis during extracorporeal circulation during hemodialysis.
Enoxaparin sodium
White or off-white powder;
The average molecular weight is 3800-5000;
Anti-Xa factor activity 90-125IU/mg;
Anti-IIa factor activity 20.0-35.0 IU / mg;
Anti-Xa factor activity and anti-IIa factor activity ratio 3.3-5.3;
Free sulfate ≤0.50%, etc., in line with the United States Pharmacopoeia, European Pharmacopoeia standards and Chinese registration standards.
A raw material for enoxaparin sodium injection.
Enoxaparin sodium injection is used to prevent deep vein thrombosis and pulmonary embolism; to treat formed venous thrombosis; to prevent the formation of thrombus during cardiopulmonary bypass; to treat unstable angina and non-Q-wave myocardial infarction.
Heparin sodium
White or off-white powder; average molecular weight 15000-19000Da; anti-IIa factor activity ≥180IU/mg, etc., in line with Chinese Pharmacopoeia, US Pharmacopoeia and European Pharmacopoeia standards
It is used as a raw material for heparin sodium injection and a raw material for producing low molecular weight heparin.
Heparin sodium injection is used to prevent thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.), diffuse intravascular coagulation (DIC) caused by various reasons, also used for hemodialysis, extracorporeal circulation Anticoagulant treatment of certain blood specimens or instruments during operation, catheterization, microvascular surgery, etc.